{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:44:22Z","timestamp":1776980662102,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005075","name":"University Medical Center Groningen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00259-019-04481-7","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T02:02:43Z","timestamp":1566612163000},"page":"529-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Diagnostic performance of FDG-PET\/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-4973","authenticated-orcid":false,"given":"F. M.","family":"Montes de Jesus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. C.","family":"Kwee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X. U.","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"van Meerten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A. J. O.","family":"Dierckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Diepstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"van der Bij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A. M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W. J. M.","family":"Glaudemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Noordzij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"key":"4481_CR1","first-page":"453","volume-title":"World Health Organization Calssification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. Post-transplant lymphoproliferative disorders (PTLD). In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al., editors. World Health Organization Calssification of Tumours of Haematopoietic and Lymphoid Tissues, vol. 2017. 4th, revised ed. Lyon: International Agency for Research on Cancer; 2017. p. 453\u201362.","edition":"4th, revised ed"},{"issue":"3","key":"4481_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s12253-010-9329-8","volume":"17","author":"G V\u00e9gso","year":"2011","unstructured":"V\u00e9gso G, Hajdu M, Sebesty\u00e9n A. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options. Pathol Oncol Res. 2011;17(3):443\u201354.","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"4481_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1432-2277.2006.00416.x","volume":"20","author":"NA Bakker","year":"2007","unstructured":"Bakker NA, van Imhoff GW, Verschuuren EAM, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int. 2007;20(3):207\u201318.","journal-title":"Transpl Int"},{"issue":"11","key":"4481_CR4","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","volume":"54","author":"D Dierickx","year":"2013","unstructured":"Dierickx D, Tousseyn T, Sagaert X, Fieuws S, Wlodarska I, Morscio J, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma. 2013;54(11):2433\u201340.","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"4481_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2009.25.4961","volume":"28","author":"AM Evens","year":"2010","unstructured":"Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038\u201346.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4481_CR6","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","volume":"31","author":"S Caillard","year":"2013","unstructured":"Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol. 2013;31(10):1302\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4481_CR7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00432-018-2674-9","volume":"144","author":"NE Wareham","year":"2018","unstructured":"Wareham NE, Mocroft A, Sengel\u00f8v H, Da Cunha-Bang C, Gustafsson F, Heilmann C, et al. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. J Cancer Res Clin Oncol. 2018;144(8):1569\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4481_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1586\/ehm.09.76","volume":"3","author":"AH Blaes","year":"2010","unstructured":"Blaes AH, Morrison VA. Post-transplant lymphoproliferative disorders following solid-organ transplantation. Expert Rev Hematol. 2010;3(1):35\u201344.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"4481_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","volume":"13","author":"R Trappe","year":"2012","unstructured":"Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196\u2013206.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4481_CR10","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/TXD.0000000000000557","volume":"2","author":"ML Nijland","year":"2016","unstructured":"Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, ten Berge IJM. Epstein-Barr virus\u2013positive posttransplant lymphoproliferative disease after solid organ transplantation. Transplant Direct. 2016;2(1):e48.","journal-title":"Transplant Direct"},{"issue":"1","key":"4481_CR11","first-page":"1","volume":"4","author":"BD Cheson","year":"2015","unstructured":"Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4(1):1\u20139.","journal-title":"Chin Clin Oncol"},{"issue":"5","key":"4481_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/cncr.21253","volume":"104","author":"CR Isasi","year":"2005","unstructured":"Isasi CR, Lu P, Blaufox MD. A metaanalysis of18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104(5):1066\u201374.","journal-title":"Cancer."},{"issue":"2","key":"4481_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2014","unstructured":"Boellaard R, Tatsch K, Pike LC, Testanera G, Kotzerke J, Graham MM, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"34","key":"4481_CR14","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","volume":"33","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Sz\u00e9kely E, et al. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish\u2013Swedish population-based study. J Clin Oncol. 2015;33(34):3993\u20138.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4481_CR15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066\u201373.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4481_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159.","journal-title":"Biometrics."},{"issue":"1","key":"4481_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.semnuclmed.2017.09.001","volume":"48","author":"TC El-Galaly","year":"2018","unstructured":"El-Galaly TC, Gormsen LC, Hutchings M. PET\/CT for staging; past, present, and future. Semin Nucl Med. 2018;48(1):4\u201316.","journal-title":"Semin Nucl Med"},{"issue":"5","key":"4481_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1365-2141.2010.08161.x","volume":"149","author":"A Parker","year":"2010","unstructured":"Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS guidelines. Br J Haematol. 2010;149(5):675\u201392.","journal-title":"Br J Haematol"},{"key":"4481_CR19","unstructured":"National Comprehensive Cancer Network. Post-transplant lymphoproliferative disorders (version 2.2015). 2015."},{"issue":"4","key":"4481_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1309\/AJCPQYYE04AVGVYI","volume":"138","author":"BP Nelson","year":"2012","unstructured":"Nelson BP, Wolniak KL, Evens A, Chenn A, Maddalozzo J, Proytcheva M. Early posttransplant lymphoproliferative disease. Am J Clin Pathol. 2012;138(4):568\u201378.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"4481_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.crad.2004.08.016","volume":"60","author":"AF Scarsbrook","year":"2005","unstructured":"Scarsbrook AF, Warakaulle DR, Dattani M, Traill Z. Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances. Clin Radiol. 2005;60(1):47\u201355.","journal-title":"Clin Radiol"},{"issue":"3","key":"4481_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3109\/10428194.2013.813501","volume":"55","author":"E Panagiotidis","year":"2014","unstructured":"Panagiotidis E, Quigley A-M, Pencharz D, Ardeshna K, Syed R, Sajjan R, et al. (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in diagnosis of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2014;55(3):515\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"4481_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3324\/haematol.2012.074500","volume":"98","author":"D Dierickx","year":"2013","unstructured":"Dierickx D, Tousseyn T, Requil\u00e9 A, Verscuren R, Sagaert X, Morscio J, et al. The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. Haematologica. 2013;98(5):771\u20135.","journal-title":"Haematologica."},{"issue":"June","key":"4481_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.09.007","volume":"132","author":"FM Montes de Jesus","year":"2018","unstructured":"Montes de Jesus FM, Kwee TC, Nijland M, Kahle XU, Huls G, Dierckx RAJO, et al. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;132(June):27\u201338.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"4481_CR25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell."},{"key":"4481_CR26","doi-asserted-by":"publisher","first-page":"150835","DOI":"10.1155\/2013\/150835","volume":"2013","author":"J Morscio","year":"2013","unstructured":"Morscio J, Dierickx D, Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol. 2013;2013:150835.","journal-title":"Clin Dev Immunol"},{"issue":"8","key":"4481_CR27","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00467-017-3627-2","volume":"32","author":"E Colombini","year":"2017","unstructured":"Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, et al. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients. Pediatr Nephrol. 2017;32(8):1433\u201342.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4481_CR28","doi-asserted-by":"publisher","first-page":"604.e1","DOI":"10.1016\/j.cmi.2015.02.002","volume":"21","author":"R San-Juan","year":"2015","unstructured":"San-Juan R, Manuel O, Hirsch HH, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, Comoli P, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin Microbiol Infect. 2015;21(6):604.e1\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"4481_CR29","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood.V83.9.2715.2715","volume":"83","author":"A Savoie","year":"1994","unstructured":"Savoie BA, Perpbte C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and. Blood. 1994:2715\u201322.","journal-title":"Blood"},{"issue":"5","key":"4481_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/rmv.582","volume":"18","author":"H Kimura","year":"2008","unstructured":"Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol. 2008;18(5):305\u201319.","journal-title":"Rev Med Virol"},{"issue":"10","key":"4481_CR31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1086\/522531","volume":"45","author":"SM Aalto","year":"2007","unstructured":"Aalto SM, Juvonen E, Tarkkanen J, Volin L, Haario H, Ruutu T, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis. 2007;45(10):1305\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4481_CR32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1128\/CMR.00006-09","volume":"23","author":"ML Gulley","year":"2010","unstructured":"Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010;23(2):350\u201366.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"4481_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1399-0012.2012.01608.x","volume":"26","author":"CJ Holman","year":"2012","unstructured":"Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transpl. 2012;26(5):741\u20137.","journal-title":"Clin Transpl"},{"key":"4481_CR34","doi-asserted-by":"crossref","unstructured":"Van Keerberghen CA, Goffin K, Vergote V, Tousseyn T, Verhoef G, Laenen A, et al. Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder. Acta Oncol (Madr). 2019","DOI":"10.1080\/0284186X.2019.1598622"},{"issue":"5","key":"4481_CR35","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/TP.0000000000002006","volume":"102","author":"H Zimmermann","year":"2018","unstructured":"Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, et al. End-of-treatment positron emission tomography after uniform first-line therapy of B-cell posttransplant lymphoproliferative disorder identifies patients at low risk of relapse in the prospective German PTLD registry. Transplantation. 2018;102(5):868\u201375.","journal-title":"Transplantation."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04481-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04481-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04481-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T23:32:37Z","timestamp":1598139157000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04481-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["4481"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04481-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]},"assertion":[{"value":"15 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"According to the Dutch Medical Research Involving Human Subject Act, the local medical ethical committee of the University Medical Center Groningen exempted approval without additional procedures. No additional informed consent was required for this retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}